Disease or Syndrome
Drug pricing watchdog ICER offers ways to increase obesity drug access
ICER, Obesity, Access, Wegovy, Policy, drug price
: BMS’ Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients
United States Food and Drug Administration, Approved, Burning Mouth Syndrome, Colorectal Carcinoma, Yervoy, first-line, Combined
Descartes-08: Sustained Efficacy in Myasthenia Gravis as Cartesian Prepares for Phase III Trial
Descartes-08 , Myasthenia Gravis (gMG) , CAR-T therapy , Cartesian Therapeutics , mRNA-based treatment , Phase III AURORA trial , Autoimmune diseases , Clinical trial results
RFK Jr. promotes measles vaccine as Texas outbreak continues
Vaccines, Texas, Measles, Disease Outbreaks, Measles-Mumps-Rubella Vaccine, Case (situation), RFK gene, Effectiveness, Vaccination, Texas
Rocket Pharmaceuticals Expands Leadership with J&J and AstraZeneca Alumni to Strengthen Gene Therapy Commercialization
Rocket Pharmaceuticals, gene therapy, commercial leadership, Sarbani Chaudhuri, Johnson & Johnson, AstraZeneca, commercial launch, gene therapy market, rare diseases, biotechnology, Kresladi, RP-L102.
Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots
Autoimmune, Autoimmune Diseases, Precision – temporal
Rallybio Halts Development of Lead FNAIT Program Following Phase 2 Failure
Rallybio RLYB212, Fetal and neonatal alloimmune thrombocytopenia (FNAIT), Phase 2 clinical trial, Maternal immune disorder therapy, Biotech pipeline shift
Cartesian reveals long-term mid-stage data for cell therapy in myasthenia gravis
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes, Myasthenia Gravis, Cell Therapy, Long-term, Cartesian
GSKs newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech
Abetalipoproteinemia, SmithKline Beecham, Bio, Grabody-B, Neurodegenerative Disorders, Blood – brain barrier anatomy, IGF1R gene
Novavaxs held-up approval package may signal warning for Covid vaccine makers
Vaccines, Approved, COVID19 (disease), United States Food and Drug Administration, Market, Novavax ‘s, Maker (occupation), Deferred